Pathophysiology and treatment options of chronic renal allograft damage

Nephrology Dialysis Transplantation

Volumn 28, Issue 10, 2013, Pages 2438-2446

  Heemann, Uwe ^a   Lutz, Jens ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

chronic allograft nephropathy; chronic rejection; pathophysiology; treatment

Indexed keywords

ALDOSTERONE; ALLOANTIBODY; ALLOANTIGEN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRASTERONE; RENIN; RENIN INHIBITOR; TACROLIMUS;

ANTIBODY MEDIATED REJECTION; ANTIGEN RECOGNITION; BLOOD GROUP ABO INCOMPATIBILITY; CELLULAR IMMUNITY; CHRONIC ALLOGRAFT NEPHROPATHY; CYTOMEGALOVIRUS INFECTION; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY PRESERVATION; KIDNEY TRANSPLANTATION; LEUKOCYTE ADHERENCE; LOW DRUG DOSE; NEPHRECTOMY; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEINURIA; REPERFUSION INJURY; REVIEW;

CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC REJECTION; PATHOPHYSIOLOGY; TREATMENT;

ALLOGRAFTS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84884927180     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft087     Document Type: Review

References (86)

1. Harlan WR, Jr, Holden KR, Williams GM et al. Proteinuria and nephrotic syndrome associated with chronic rejection of kidney transplants. N Engl J Med 1967; 277: 769-776
2. Hume DM, Merrill JP, Miller BF et al. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955; 34: 327-382
3. Paul LC. Chronic renal transplant loss. Kidney Int 1995; 47: 1491-1499
4. Hancock WH, Whitley WD, Tullius SG et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643-650 (Pubitemid 23293031)
5. Merrill JP, Murray JE, Harrison JH et al. Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc 1956; 160: 277-282
6. Tilney NL. Renal transplantation between identical twins: a review. World J Surg 1986; 10: 381-388
7. Kirkman RL, Strom TB, Weir MR et al. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982; 34: 347-351 (Pubitemid 13170993)
8. Kessaris N, Mukherjee D, Chandak P et al. Renal transplantation in identical twins in United States and United Kingdom. Transplantation 2008; 86: 1572-1577
9. Tullius SG, Heemann U, Hancock WW et al. Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection. Ann Surg 1994; 220: 425-432; discussion 432-5
10. Hoy WE, Douglas-Denton RN, Hughson MD et al. A stereological study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy. Kidney Int 2003; 83; S31-S37 (Pubitemid 36126840)
11. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760 (Pubitemid 351347767)
12. Najafian B, Kasiske BL. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2008; 17: 149-155 (Pubitemid 351253039)
13. Pratschke J, Wilhelm MJ, Laskowski I et al. Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 2001; 12: 2474-2481 (Pubitemid 33021126)
14. Szabo A, Heemann U. Ischemia reperfusion injury and chronic allograft rejection. Transplant Proc 1998; 30: 4281-4284 (Pubitemid 29013225)
15. Laskowski IA, Pratschke J, Wilhelm MM et al. Early and late injury to renal transplants from non-heart-beating donors. Transplantation 2002; 73: 1468-1473
16. Cicora F, Roberti J, Vasquez D et al. Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model. Clin Exp Immunol 2012; 167: 169-177
17. Tullius SG, Heemann UW, Azuma H et al. Alloantigen-independent factors lead to signs of chronic rejection in long-term kidney isografts. Transpl Int 1994; 7(Suppl. 1): S306-S307
18. Gueler F, Gwinner W, Schwarz A et al. Long-term effects of acute ischemia and reperfusion injury. Kidney Int 2004; 66: 523-527 (Pubitemid 38981991)
19. Bidmon B, Kratochwill K, Rusai K et al. Increased immunogenicity is an integral part of the heat shock response following renal ischemia. Cell Stress Chaperones 2012; 17: 385-397
20. Shimizu I, Smith NR, Zhao G et al. Decay-accelerating factor prevents acute humoral rejection induced by low levels of antialphaGal natural antibodies. Transplantation 2006; 81: 95-100 (Pubitemid 43122155)
21. Dalmasso AP, Vercellotti GM, Platt JL et al. Inhibition of complement- mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530-533
22. Mackenzie HS, Tullius SG, Heemann UW et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 1994; 94: 2148-2152 (Pubitemid 24348258)
23. Pawlik A, Florczak M, Masiuk M et al. The expansion of CD4 +CD28-T cells in patients with chronic kidney graft rejection. Transplant Proc 2003; 35: 2902-2904 (Pubitemid 38102085)
24. Obata F, Yoshida K, Ohkubo M et al. Contribution of CD4+ and CD8+ T cells and interferon-gamma to the progress of chronic rejection of kidney allografts: the Th1 response mediates both acute and chronic rejection. Transpl Immunol 2005; 14: 21-25 (Pubitemid 40462285)
25. Obata F, Yoshida K, Ikeda Y et al. Clonality analysis of T cells mediating acute and chronic rejection in kidney allografts. Transpl Immunol 2004; 13: 233-237 (Pubitemid 39285979)
26. Thierry A, Thervet E, Vuiblet V et al. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. Am J Transplant 2011; 11: 2153-2161
27. Ripoll E, Nacher V, Vidal A et al. Cold ischaemia, innate immunity and deterioration of the glomerular filtration barrier in antibody- mediated acute rejection. Nephrol Dial Transplant 2012; 27: 3296-3305
28. Sellares J, de Freitas DG, Mengel M et al. Understanding the causes of kidney transplant failure: the dominant role of antibody- mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399
29. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531
30. Latinne D, Vitiello DM, Sachs DH et al. Tolerance to discordant xenografts. I. Sharing of human natural antibody determinants on miniature swine bone marrow cells and endothelial cells. Transplantation 1994; 57: 238-245 (Pubitemid 24048592)
31. Lin Y, Soares MP, Sato K et al. Accommodated xenografts survive in the presence of anti-donor antibodies and complement that precipitate rejection of naive xenografts. J Immunol 1999; 163: 2850-2857 (Pubitemid 29399215)
32. Thielke JJ, West-Thielke PM, Herren HL et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87: 268-273
33. Allen G, Simpkins CE, Segev D et al. Rapid accomodation of an A1 renal allograft after preconditioning for ABO-incompatible transplantation. Diab Kidney 2009; 162: 35-46
34. Sis B, Kaplan B, Halloran PF. Histologic findings from positive crossmatch or ABO-incompatible renal allografts: accommodation or chronic allograft injury? Am J Transplant 2006; 6: 1753-1754. (Pubitemid 44024944)
35. Reinke P, Fietze E, Ode-Hakim S et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344: 1737-1738
36. Muller V, Becker G, Delfs M et al. Do urinary tract infections trigger chronic kidney transplant rejection in man? J Urol 1998; 159: 1826-1829. (Pubitemid 29190705)
37. Babel N, Schwarzmann F, Prang N et al. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. Transplantation 2001; 72: 736-739 (Pubitemid 32802763)
38. Nankivell BJ, Borrows RJ, Fung CL et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565 (Pubitemid 39097102)
39. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4: 2029-2034
40. Peschke B, Scheuermann EH, Geiger H et al. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 1999; 51: 290-295 (Pubitemid 29219296)
41. Dupont PJ, Manuel O, Pascual M. Infection and chronic allograft dysfunction. Kidney Int Suppl 2010; 119:S47-S53
42. de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol 2008; 4: 252-264 (Pubitemid 351589731)
43. Thomas LD, Milstone AP, Vilchez RA et al. Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. Transplantation 2009; 88: 360-366
44. Hirsch HH, Suthanthiran M. The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation. Nat Clin Pract Nephrol 2006; 2: 240-241 (Pubitemid 43787251)
45. Briganti EM, Russ GR, McNeil JJ et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103-109 (Pubitemid 34753480)
46. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249: F324-F337 (Pubitemid 16225762)
47. Anderson S, Meyer TW, Rennke HG et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619 (Pubitemid 15227525)
48. Ruggenenti P, Porrini EL, Gaspari F et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35: 2061-2068
49. Delanaye P, Weekers L, Dubois BE et al. Outcome of the living kidney donor. Nephrol Dial Transplant 2012; 27: 41-50
50. Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380 (Pubitemid 34925248)
51. Sijpkens YW, Joosten SA, Wong MC et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65: 2409-2418 (Pubitemid 38670027)
52. Joosten SA, van Kooten C, Sijpkens YW et al. The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging. Kidney Int 2004; 65: 1556-1559 (Pubitemid 38591000)
53. Teteris SA, Hochheiser K, Kurts C. Isolation of functional dendritic cells from murine kidneys for immunological characterization. Nephrology (Carlton) 2012; 17: 364-371
54. Hochheiser K, Engel DR, Hammerich L et al. Kidney dendritic cells become pathogenic during crescentic glomerulonephritis with proteinuria. J Am Soc Nephrol 2011; 22: 306-316
55. Lutz J, Yao Y, Song E et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 2005; 79: 655-661 (Pubitemid 40463171)
56. Viklicky O, Zou H, Muller V et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497-502 (Pubitemid 30129579)
57. Lutz J, Huang H, Deng M et al. The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. Transplantation 2007; 83: 741-746 (Pubitemid 46569192)
58. Schnuelle P, Gottmann U, Hoeger S et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009; 302: 1067-1075
59. Faenza A, Catena F, Nardo B et al. Kidney preservation with university of Wisconsin and Celsior solution: a prospective multicenter randomized study. Transplantation 2001; 72: 1274-1277 (Pubitemid 33026608)
60. Baatard R, Pradier F, Dantal J et al. Prospective randomized comparison of University of Wisconsin and UW-modified, lacking hydroxyethyl-starch, cold-storage solutions in kidney transplantation. Transplantation 1993; 55: 31-35 (Pubitemid 23033941)
61. Ploeg RJ. Kidney preservation with the UW and Euro-Collins solutions. A preliminary report of a clinical comparison. Transplantation 1990; 49: 281-284 (Pubitemid 20088161)
62. Moers C, Pirenne J, Paul A et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2012; 366: 770-771
63. Roodnat JI, van Riemsdijk IC, Mulder PG et al. The superior results of living-donor renal transplantation are not completely caused by selection or short cold ischemia time: a single-center, multivariate analysis. Transplantation 2003; 75: 2014-2018 (Pubitemid 36793284)
64. Kahan BD, Stepkowski S, Kilic M et al. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplantation 2004; 78: 858-863 (Pubitemid 39298529)
65. Hamar P, Liu S, Viklicky O et al. Cyclosporine A and azathioprine are equipotent in chronic kidney allograft rejection. Transplantation 2000; 69: 1290-1295 (Pubitemid 30238713)
66. Szabo A, Lutz J, Schleimer K et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57: 982-991 (Pubitemid 30434788)
67. Lutz J, Risch K, Liu S et al. Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. Kidney Int 2006; 70: 1080-1088 (Pubitemid 44344078)
68. Tang SC, Chan KW, Tang CS et al. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. Nephrol Dial Transplant 2006; 21: 3243-3251 (Pubitemid 44567101)
69. Mehra MR, Uber PA. TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit? J Heart Lung Transplant 2003; 22: 501-504. (Pubitemid 36549047)
70. Albano L, Alamartine E, Toupance O et al. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study. Ann Transplant 2012; 17: 58-67
71. Meier-Kriesche HU, Merville P, Tedesco-Silva H et al. Mycophenolate mofetil initiation in renal transplant patients at different times posttransplantation: the TranCept Switch study. Transplantation 2011; 91: 984-990
72. Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. J Am Soc Nephrol 2010; 21: 2157-2168
73. Petrova DT, Brandhorst G, Brehmer F et al. Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function. Ther Drug Monit 2010; 32: 405-412
74. Lederer SR, Friedrich N, Banas B et al. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clin Transplant 2005; 19: 168-174 (Pubitemid 40424886)
75. Asberg A, Midtvedt K, Line PD et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 62-68 (Pubitemid 44296979)
76. Mourer JS, Hartigh J, van Zwet EW et al. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation 2012; 93: 887-894
77. Pestana JO, Grinyo JM, Vanrenterghem Y et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639
78. Grinyo J, Charpentier B, Pestana JM et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521-1527
79. Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587-1596
80. Waiser J, Budde K, Schutz M et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2012; 27: 1246-1251
81. Fritsche L, Horstrup J, Budde K et al. Old-for-old kidney allocation allows successful expansion of the donor and recipient pool. Am J Transplant 2003; 3: 1434-1439 (Pubitemid 37288090)
82. Page EK, Dar WA, Knechtle SJ. Biologics in organ transplantation. Transpl Int 2012; 25: 707-719
83. Sureshkumar KK, Hussain SM, Marcus RJ et al. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. Clin Nephrol 2012; 77: 246-253
84. Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413
85. Muller V, Szabo A, Viklicky O et al. Sex hormones and genderrelated differences: their influence on chronic renal allograft rejection. Kidney Int 1999; 55: 2011-2020 (Pubitemid 29197991)
86. Antus B, Yao Y, Liu S et al. Contribution of androgens to chronic allograft nephropathy is mediated by dihydrotestosterone. Kidney Int 2001; 60: 1955-1963 (Pubitemid 33000002)